NCT03161015View on ClinicalTrials.gov

Single-Dose PK Study of GBT440 in Subjects With Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

May 25, 2017

Study Completion Date

July 6, 2017

Conditions
Renal Impairment
Interventions
DRUG

GBT440

Oral

Trial Locations (2)

32809

OCRC, Orlando

33136

University of Miami, Miami

Sponsors
All Listed Sponsors
lead

Global Blood Therapeutics

INDUSTRY

NCT03161015 - Single-Dose PK Study of GBT440 in Subjects With Renal Impairment | Biotech Hunter | Biotech Hunter